Literature DB >> 28377639

NASH: Novel therapeutic strategies targeting ASK1 in NASH.

Susanne Schuster1, Ariel E Feldstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28377639     DOI： 10.1038/nrgastro.2017.42

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

Review 1.  Role of MAPKs in development and differentiation: lessons from knockout mice.

Authors:  M Aouadi; B Binetruy; L Caron; Y Le Marchand-Brustel; F Bost
Journal:  Biochimie       Date:  2006-06-27       Impact factor: 4.079

2.  Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice.

Authors:  Hongliang Li; Qi-Zhu Tang; Chen Liu; Mark Moon; Manyin Chen; Ling Yan; Zhou-Yan Bian; Yan Zhang; Ai-Bing Wang; Mai P Nghiem; Peter P Liu
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

3.  Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.

Authors:  Pi-Xiao Wang; Yan-Xiao Ji; Xiao-Jing Zhang; Ling-Ping Zhao; Zhen-Zhen Yan; Peng Zhang; Li-Jun Shen; Xia Yang; Jing Fang; Song Tian; Xue-Yong Zhu; Jun Gong; Xin Zhang; Qiao-Fang Wei; Yong Wang; Jing Li; Lu Wan; Qingguo Xie; Zhi-Gang She; Zhihua Wang; Zan Huang; Hongliang Li
Journal:  Nat Med       Date:  2017-02-20       Impact factor: 53.440

4.  DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.

Authors:  Lanfeng Xie; Pi-Xiao Wang; Peng Zhang; Xiao-Jing Zhang; Guang-Nian Zhao; Aibing Wang; Junhong Guo; Xueyong Zhu; Qin Zhang; Hongliang Li
Journal:  J Hepatol       Date:  2016-03-23       Impact factor: 25.083

Review 5.  From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.

Authors:  Alexander Wree; Lori Broderick; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-20       Impact factor: 46.802

6.  ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis.

Authors:  K Tobiume; A Matsuzawa; T Takahashi; H Nishitoh; K Morita ; K Takeda; O Minowa; K Miyazono; T Noda; H Ichijo
Journal:  EMBO Rep       Date:  2001-03       Impact factor: 8.807

7.  Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.

Authors:  Mei Xiang; Pi-Xiao Wang; Ai-Bing Wang; Xiao-Jing Zhang; Yaxing Zhang; Peng Zhang; Fang-Hua Mei; Man-Hua Chen; Hongliang Li
Journal:  J Hepatol       Date:  2016-02-06       Impact factor: 25.083

Review 8.  Pleiotropic properties of ASK1.

Authors:  Chihiro Sakauchi; Hiroaki Wakatsuki; Hidenori Ichijo; Kazuki Hattori
Journal:  Biochim Biophys Acta Gen Subj       Date:  2016-09-30       Impact factor: 3.770

9.  Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.

Authors:  Ariel E Feldstein; Ali Canbay; Paul Angulo; Makiko Taniai; Lawrence J Burgart; Keith D Lindor; Gregory J Gores
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

Review 10.  Apoptosis signal-regulating kinase 1 as a therapeutic target.

Authors:  Yosuke Kawarazaki; Hidenori Ichijo; Isao Naguro
Journal:  Expert Opin Ther Targets       Date:  2014-03-24       Impact factor: 6.902
  10 in total
  11 in total

Review 1.  Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.

Authors:  Ming-Ming Chen; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-02

Review 2.  Innate immune regulatory networks in hepatic lipid metabolism.

Authors:  Lan Bai; Hongliang Li
Journal:  J Mol Med (Berl)       Date:  2019-03-19       Impact factor: 4.599

3.  Systematic Identification of Regulators of Oxidative Stress Reveals Non-canonical Roles for Peroxisomal Import and the Pentose Phosphate Pathway.

Authors:  Michael M Dubreuil; David W Morgens; Kanji Okumoto; Masanori Honsho; Kévin Contrepois; Brittany Lee-McMullen; Gavin McAllister Traber; Ria S Sood; Scott J Dixon; Michael P Snyder; Yukio Fujiki; Michael C Bassik
Journal:  Cell Rep       Date:  2020-02-04       Impact factor: 9.423

4.  ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model.

Authors:  Susanne Schuster-Gaul; Lukas Jonathan Geisler; Matthew D McGeough; Casey D Johnson; Anna Zagorska; Li Li; Alexander Wree; Vivian Barry; Igor Mikaelian; Lily J Jih; Bettina G Papouchado; Grant Budas; Hal M Hoffman; Ariel E Feldstein
Journal:  JCI Insight       Date:  2020-01-30

5.  Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets.

Authors:  Seonghwan Hwang; Yong He; Xiaogang Xiang; Wonhyo Seo; Seung-Jin Kim; Jing Ma; Tianyi Ren; Seol Hee Park; Zhou Zhou; Dechun Feng; George Kunos; Bin Gao
Journal:  Hepatology       Date:  2020-03-16       Impact factor: 17.298

6.  Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH.

Authors:  Yu-Feng Li; Zhi-Fu Xie; Qian Song; Jing-Ya Li
Journal:  Acta Pharmacol Sin       Date:  2022-02-01       Impact factor: 7.169

Review 7.  Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches.

Authors:  Kook Hwan Kim; Myung-Shik Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-24       Impact factor: 5.555

Review 8.  Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.

Authors:  James J Connolly; Kohtaro Ooka; Joseph K Lim
Journal:  J Clin Transl Hepatol       Date:  2018-06-28

Review 9.  Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology.

Authors:  In Cheol Yoon; Jong Ryeol Eun
Journal:  Yeungnam Univ J Med       Date:  2019-04-11

10.  Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases.

Authors:  Yun Seok Kim; Sang Geon Kim
Journal:  Clin Mol Hepatol       Date:  2020-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.